tiprankstipranks
In this article:
Blurbs

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Mereo Biopharma Group Plc (MREO)

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRKResearch Report) and Mereo Biopharma Group Plc (MREOResearch Report) with bullish sentiments.

Merck & Company (MRK)

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company, with a price target of $100.00. The company’s shares closed last Wednesday at $76.05.

According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 14.1% and a 42.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $90.31, which is a 19.7% upside from current levels. In a report issued on December 8, Wells Fargo also initiated coverage with a Buy rating on the stock with a $90.00 price target.

See today’s best-performing stocks on TipRanks >>

Mereo Biopharma Group Plc (MREO)

Needham analyst Gil Blum maintained a Buy rating on Mereo Biopharma Group Plc today and set a price target of $10.00. The company’s shares closed last Wednesday at $1.64, close to its 52-week low of $1.51.

According to TipRanks.com, Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -26.0% and a 15.2% success rate. Blum covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Rocket Pharmaceuticals, and Aeglea Biotherapeutics.

Currently, the analyst consensus on Mereo Biopharma Group Plc is a Strong Buy with an average price target of $10.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MRK:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed